Stock Events

Biohit Oyj B 

€2.35
4
+€0+0% Friday 15:29

Statistics

Day High
2.38
Day Low
2.3
52W High
2.4
52W Low
1.8
Volume
22,928
Avg. Volume
10,946
Mkt Cap
32.32M
P/E Ratio
17.75
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

13JunExpected
Q2 2015
Q3 2015
Q4 2015
Q4 2017
Q1 2018
Q4 2018
Q1 2024
-0.1
-0.07
-0.04
-0.01
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BIOBV.HE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company's diagnostic tests product includes the GastroPanel Unified test panel for stomach health check; GastroPanel Four-in-One stomach test; GastroSoft software application to assist clinicians and general practitioner; Biohit Active B12, a test for measuring the levels of active vitamin B12; BIOHIT Total 25OH Vitamin D, a test for determination of vitamin D status; and Biohit Calprotectin test for measuring human calprotectin. It also offers GastroPanel quick test NT, a quantitative immunochromatographic test for the detection of Helicobacter pylori (H. Pylori) and atrophic gastritis; BIOHIT Celiac Quick test for diagnosis of celiac disease; Biohit ColonView Quick test, a test for detection of fecal occult blood; Biohit Helicobacter Pylori UFT300 and Helicobacter Pylori Quick test methods to detect H. pylori infection; and Lactose Intolerance quick test to support the diagnosis of lactose intolerance in a duodenal biopsy specimen. In addition, the company provides acetaldehyde-binding products, such as Acetium capsules that are intended for persons with a low-acid or anacidic stomach; and Acetium lozenge, which helps in quitting smoking; and monoclonal antibodies for use in the areas of cellular pathology, neurobiology, oncology, and human gastric biomarkers research. The company was incorporated in 1988 and is headquartered in Helsinki, Finland.
Show more...
CEO
Prof. Osmo Antero Suovaniemi M.D., Ph.D.
Employees
46
Country
FI
ISIN
FI0009005482

Listings